Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors –– Jost Fischer, Chairman of ...

South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...

Subsequently, its second biosimilar product, Reditux, was launched in the domestic market in 2007. The company now has many more biosimilars in the pipeline, which are expected to be launched in ...

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Alvotech (NASDAQ:ALVO – Get Free Report) is expected to issue its quarterly earnings data after the market closes on ...